PAT-048
PAT-048 is a potent, selective and orally active autotaxin inhibitor, inhibits IL-6 mRNA expression, but shows no effect on autotaxin protein and pulmonary lysophosphatidic acid (LPA) production in lung fibrosis model. PAT-048 shows an IC50 and IC90 of 20 nM and 200 nM for autotaxin in mouse plasma. PAT-048 reduces dermal fibrosis in vivo.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1359983-15-5
- Fòrmula: C22H18ClF2N3O2S
- Peso molecular:461.91
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
IC50 & Target
IC50: 20 nM (Autotaxin, in mouse plasma)[1]
IC90: 200 nM (Autotaxin, in mouse plasma)[1]
Chemical Information
-
No. CAS 1359983-15-5
-
Peso molecular 461.91
-
Fòrmula C22H18ClF2N3O2S
-
SMILES
CCCN1N=CC(N2C3=C(C(SC4=CC=CC(C(O)=O)=C4F)=C2C)C=CC(Cl)=C3F)=C1
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Castelino FV, et al. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis. Arthritis Rheumatol. 2016 Dec;68(12):2964-2974. [Content Brief]
[2]. Black KE, et al. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis. FASEB J. 2016 Jun;30(6):2435-50. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PAT-048 Related Classifications
HY-123522 Related Classifications
Powered by Bioz